A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

NCT07634471 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

960

Enrollment

INDUSTRY

Sponsor class

Conditions

Follicular Lymphoma

Interventions

BIOLOGICAL: MK-1045
BIOLOGICAL: Rituximab
BIOLOGICAL: Rituximab biosimilar
DRUG: Bendamustine
DRUG: Cyclophosphamide
DRUG: Vincristine
DRUG: Prednisone
DRUG: Prednisolone
DRUG: Doxorubicin Hydrochloride

Sponsor

Merck Sharp & Dohme LLC